Summary: In 85 adults with poorly controlled type 2 diabetes who were all starting a GLP-1 receptor agonist, a six-month digital education programme delivered through social networks and a “Digital Coach” was compared against usual care in an open-label multicentre Spanish randomised trial. Greater reductions were observed in the intervention arm for HbA1c (3.7% vs 2.6%; P=.006), body weight (-8.7 kg vs -4.9 kg; P=.002), and fasting glucose, alongside improved medication adherence and patient-reported experience.
PICO Summary
| Element | Detail |
|---|---|
| Population | 85 adults with type 2 diabetes mellitus and poor metabolic control, all commencing a GLP-1 receptor agonist; multicentre, randomised, prospective, open-label design conducted in Spain. |
| Intervention | Structured six-month digital education programme delivering lifestyle change support through social networks and digital tools, with weekly and on-demand advice from a “Digital Coach” (n=44). |
| Comparison | Usual care, comprising standard clinical follow-up without digital augmentation (n=41). |
| Outcome | Mean change favoured the intervention for HbA1c reduction (3.7%, SD 1.9% vs 2.6%, SD 2.1%; t=2.54; P=.006), body weight (-8.7, SD 6.1 kg vs -4.9, SD 5.0 kg; t=-3.13; P=.002), BMI (-3.0 vs -1.8 kg/m²; P=.006), and fasting plasma glucose reduction (122.6 vs 70.5 mg/dL; P=.004). Medication adherence improved with the intervention but worsened with usual care (+13.8% vs -8%; P=.01), and patient-reported experience improved only in the intervention arm. No 95% confidence intervals, absolute risk reduction, or number-needed-to-treat were reported; no significant adverse effects were described. |
Digital education programme in type 2 diabetes
RCT · type 2 diabetes · 6 months
Added to GLP-1 therapy, a 6-month digital education programme produced larger HbA1c, weight, and adherence gains than usual care. Open-label and small, so the benefit is an incremental adjunct rather than proven standalone effect.
Expert Commentary
This is an encouraging but preliminary signal rather than definitive evidence. The verdict is cautiously positive: across glycaemic, anthropometric, and adherence measures, the digitally supported arm outperformed usual care, and the between-group differences reached conventional significance. The effect sizes are nonetheless reported only as mean changes with standard deviations, without confidence intervals or absolute measures, which limits how precisely the benefit can be quantified. The single most weighed limitation is the open-label design layered onto a small sample of 85 participants. Behavioural and patient-reported outcomes such as adherence, satisfaction, and self-reported knowledge are especially vulnerable to expectation effects when neither participants nor coaches are blinded, and a trial this size is easily swayed by a handful of outliers. A further structural caveat deserves emphasis: every participant was simultaneously starting a GLP-1 receptor agonist, so the striking weight and HbA1c reductions in both arms reflect potent pharmacotherapy, with the digital programme contributing an incremental, not standalone, effect. Can I use this with my patients? Tentatively yes, for motivated adults newly started on a GLP-1 agonist who can engage with digital coaching, but as an adjunct rather than a substitute for structured care. Larger blinded-outcome trials with confidence intervals and durable follow-up are needed before this becomes standard practice.
References
Caballero Mateos I, Morales Portillo C, Lainez López M, Vilches-Arenas Á. Efficacy of a Digital Educational Intervention for Patients With Type 2 Diabetes Mellitus: Multicenter, Randomized, Prospective, 6-Month Follow-Up Study. J Med Internet Res. 2025;27:e60758. doi:10.2196/60758